-
2023-506876-28-00
5
2024-08-01
The medical condition we are investigating is type 1 AMI (STEMI and NS
-
2023-510178-15-00
5
2024-07-31
High-risk Large B-cell Lymphoma
-
2024-511252-41-00
5
2024-07-30
Patients with biochemical recurrence after primary treatment of prosta
-
2023-507204-31-00
5
2024-07-26
Hidradenitis Suppurativa
-
2022-501392-81-00
6
2024-07-25
Obesity
-
2023-505746-25-00
4
2024-07-16
Cold agglutinin disease
-
2023-505592-69-00
5
2024-07-12
Carcinoma of Unknown Primary
-
2022-502781-24-01
5
2024-06-05
ASCVD - Atherosclerotic Cardiovascular Disease
-
2023-506906-38-00
5
2024-05-23
Follicular Lymphoma
-
2023-506669-70-00
5
2024-04-30
Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).
-
2023-506948-17-00
5
2024-04-05
Previously Untreated Chronic Lymphocytic Leukemia
-
2023-507059-32-00
3
2024-02-21
To restore coagulation in patients taking DOACs who are experiencing b
-
2023-503827-25-01
5
2024-02-16
Non-Small Cell Lung Cancer (NSCLC)
-
2023-505268-12-00
5
2024-02-09
Treatment-resistant depression
-
2023-505870-13-00
3
2024-01-11
Extra-pulmonary neuroendocrine carcinoma (epNEC)
-
2023-506139-13-00
5
2024-01-04
Treatment naïve patients with MF
-
2022-502669-14-00
5
2023-12-18
Small cell lung cancer (SCLC)
-
2023-505976-31-00
5
2023-11-24
Systemic Sclerosis (SSc) presenting with Limited or Diffuse Cutaneous
-
2023-505023-31-00
5
2023-11-17
Renal cell carcinoma
-
2022-501863-41-00
5
2023-11-13
Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
-
2023-503484-42-00
7
2023-10-19
Advanced, metastatic, solid malignancy
-
2022-501343-33-00
5
2023-10-18
Biochemically recurrent prostate cancer
-
2024-512616-21-00
4
2023-10-18
HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tu
-
2023-504817-56-00
6
2023-09-05
Bronchiolitis